

Table S2. 14 drugs approved from the 798 projects begun between 1991 and 2010.

Drug Name	Active Ingredients	Indication	Originator	Company	Approval Year of FDA	Review Priority; Orphan Status
Alex	loteprednol etabonate	Seasonal allergic conjunctivitis	University of Florida	ausch & Lomb Pharmaceuticals, Inc.	1998	Standard
Emtriva	emtricitabine	HIV infection	Emory University	Gilead Sciences, Inc.	2003	Standard
Myozyme	alglucosidase alfa	Pompe disease	Duke University	Genzyme Corporation	2006	N/A; Orphan
Relistor	methylnaltrexone bromide	Treatment of opioid-induced constipation	University of Chicago	Progenics Pharmaceuticals, Inc.	2008	Standard
Krystexxa	pegloticase	Chronic gout	Duke University	Savient Pharmaceuticals, Inc.	2010	N/A; Orphan
Kyprolis	carfilzomib	Multiple myeloma	Yale University	Onyx Pharmaceuticals, Inc	2012	Standard; Orphan
Amyvid	florbetapir (18F)	Positron Emission Tomography imaging for Alzheimer's disease	University of Pennsylvania	Eli Lilly and Company	2012	PRIORITY
Vizamyl	flutemetamol (18F)	Positron Emission Tomography imaging for Alzheimer's disease	University of Pittsburgh	Cardinal Health for GE Health care	2013	Standard
Lymphoseek	technetium Tc 99m tilmanocept	Radioactive diagnostic agent for breast cancer or melanoma	University of California San Diego	Navidea Biopharmaceuticals	2013	Standard
Cerdelga	eliglustat tartrate	Gaucher disease type 1	University of Michigan	Genzyme Ireland, Ltd.	2014	Priority; Orphan
Neuraceq	florbetaben (18F)	Positron Emission Tomography imaging for Alzheimer's disease	University of Pennsylvania	Piramal Imaging	2014	Standard
Strensiq	susoctocog alfa	Perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)	Emory University	Alexion Pharmaceuticals, Inc.	2015	N/A; Orphan
Carmeseal-MD	Carmeseal	Duchenne muscular dystrophy	University of Michigan	Phrixus Pharmaceuticals, Inc. EthicorPharma Ltd.	Not approved by the FDA Available in European Access Program since 2015	N/A
Fulstan/Hornel	falecalcitriol	Hypoparathyroidism, Osteomalacia, Rickets, Secondary hyperparathyroidism	University of Wisconsin-Madison	Kissei Pharmaceutical Co Ltd or Taisho Pharmaceutical Co Ltd	Not approved by the FDA Approved in Japan in 2001	N/A